PepGen’s stock skyrockets on record-breaking DM1 trial data
PepGen's stock surged 132% after its Phase II trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1) met endpoints, showing high genetic modulation and functional improvements. The stock later closed at $4.61, up 92.9% from the previous close. The trial demonstrated significant splicing correction and tolerability, with data supporting continued development. PepGen expects more data in 2027.
How this was made

The 30-second read
Why it matters
The data positions PepGen as a leading candidate in the DM1 therapeutic space, potentially attracting partnership interest and boosting its valuation.
Market read
First‑report of a breakthrough Phase II trial for a rare disease, driving a sharp stock rally and likely influencing the broader gene‑therapy sector.
What to watch
Small patient cohort (6 treated) and lack of long‑term safety data could temper enthusiasm.
Background
PepGen (Nasdaq: PGN) announced its FREEDOM2‑DM1 Phase II trial results, showing unprecedented splicing correction and functional gains in myotonic dystrophy type 1 patients.
Market effects
May boost sentiment for the rare‑disease gene‑therapy sector and other DM1‑focused biotech firms.
Primarily affects US‑listed biotech investors; limited broader market effect.
Highlights progress in antisense oligonucleotide therapies, relevant to global biotech R&D pipelines.
Counterpoint
Phase II success does not guarantee Phase III outcomes; investors may wait for larger trials before committing.
Key entities
- CompanyPepGen
Nasdaq‑listed biotech developing antisense oligonucleotide therapies.
- ResearcherDr. Hanns Lochmüller
Study investigator providing expert commentary on trial significance.

